HISUN(SH:600267) Ge Long Hui A P P·2026-02-24 08:53Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for its raw material drug Ticagrelor from the European Directorate for the Quality of Medicines & HealthCare (EDQM), indicating the quality recognition of this drug in the European market and enhancing the company's potential for international market expansion [1] Group 1 - The CEP certification for Ticagrelor signifies the drug's suitability for treating Acute Coronary Syndrome (ACS) and its effectiveness in reducing cardiovascular death, myocardial infarction, and stroke in ACS patients or those with a history of myocardial infarction [1] - The original manufacturer of Ticagrelor is AstraZeneca, highlighting the competitive landscape in the pharmaceutical industry [1] - The certification allows the raw material to enter the EU market and other markets that recognize the CEP certificate, which is expected to have a positive impact on the company's international market expansion efforts [1]